Get the Stockscreener App
0.40
4.68%
0.0179
After Hours:
.40
Spruce Biosciences Inc stock is traded at $0.40, with a volume of 320.82K.
It is up +4.68% in the last 24 hours and down -18.37% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
See More
Previous Close:
$0.3821
Open:
$0.3821
24h Volume:
320.82K
Relative Volume:
0.57
Market Cap:
$16.52M
Revenue:
$9.57M
Net Income/Loss:
$-43.11M
P/E Ratio:
-0.2395
EPS:
-1.67
Net Cash Flow:
$-49.54M
1W Performance:
+4.38%
1M Performance:
-18.37%
6M Performance:
-24.53%
1Y Performance:
-75.61%
1-Day Range:
$0.373
$0.40
1-Week Range:
$0.373
$0.418
52-Week Range:
$0.37
$5.95
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
0.40 | 16.52M | 9.57M | -43.11M | -49.54M | -1.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter
HC Wainwright Has Bullish Estimate for SPRB FY2024 Earnings - Defense World
Spruce Biosciences (NASDAQ:SPRB) Given “Neutral” Rating at HC Wainwright - Defense World
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why - MSN
Spruce Biosciences' SWOT analysis: tildacerfont trials shape stock outlook - Investing.com
Spruce Biosciences’ (SPRB) Neutral Rating Reiterated at Guggenheim - Defense World
FY2024 Earnings Forecast for SPRB Issued By Leerink Partnrs - Defense World
Needham & Company LLC Reiterates Buy Rating for Recursion Pharmaceuticals (NASDAQ:RXRX) - Defense World
Rigel Pharmaceuticals’ (RIGL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Spruce Biosciences (NASDAQ:SPRB) Earns “Market Perform” Rating from Oppenheimer - Defense World
Mizuho Cuts Revance Therapeutics (NASDAQ:RVNC) Price Target to $3.10 - Defense World
Spruce Biosciences (NASDAQ:SPRB) Earns “Market Perform” Rating from JMP Securities - Defense World
Spruce Biosciences (NASDAQ:SPRB) Earns “Sector Perform” Rating from Royal Bank of Canada - Defense World
Telsey Advisory Group Increases Stitch Fix (NASDAQ:SFIX) Price Target to $6.00 - Defense World
Sirius XM (NASDAQ:SIRI) Earns “Buy” Rating from Guggenheim - Defense World
Wells Fargo & Company Initiates Coverage on Summit Therapeutics (NASDAQ:SMMT) - Defense World
Wells Fargo & Company Reaffirms “Equal Weight” Rating for RxSight (NASDAQ:RXST) - Defense World
Solid Biosciences (NASDAQ:SLDB) Research Coverage Started at JMP Securities - Defense World
Citizens Jmp Downgrades Spruce Biosciences (NASDAQ:SPRB) to Hold - Defense World
SPRB stock touches 52-week low at $0.41 amid market challenges - Investing.com Australia
Clinical Trials News Live Feed - StockTitan
Arnold Schwarzenegger is joining a Fortune 500 company to solve a great problem of his generation - Yahoo Finance
Spruce Biosciences downgraded to Market Perform from Outperform at JMP - MSN
Spruce Biosciences to wind down investment for genetic disorder drug - MSN
JMP Securities Downgrades Spruce Biosciences (SPRB) - MSN
SPRB stock touches 52-week low at $0.41 amid market challenges By Investing.com - Investing.com South Africa
Spruce stock outlook reduced as tildacerfont falls short, company explores alternatives - Investing.com Canada
Oppenheimer Downgrades Spruce Biosciences (SPRB) - MSN
Spruce Biosciences stock downgraded after trial miss By Investing.com - Investing.com Canada
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder - Yahoo Finance
Spruce Biosciences stock downgraded after trial miss - Investing.com
Spruce Biosciences downgraded to Perform from Outperform at Oppenheimer - TipRanks
Oppenheimer cuts Spruce Biosciences to perform By Investing.com - Investing.com UK
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH - The Bakersfield Californian
Congenital Adrenal Hyperplasia Clinical Trials 2024: EMA, - openPR
Company News for Dec 10, 2024 - Yahoo Finance
Spruce Biosciences Halts CAH Drug Program After Phase 2 Trial Misses Key Endpoint - StockTitan
Layoff Tracker: CDMOs Cut Costs With AmplifyBio and Resilience Layoffs - BioSpace
UBS Initiates Coverage of Glaukos (GKOS) with Buy Recommendation - MSN
Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock By Investing.com - Investing.com UK
Spruce Biosciences stock holds potential as Oppenheimer targets upcoming Phase 2b results - Investing.com Australia
Spruce Biosciences stock holds potential as Oppenheimer targets upcoming Phase 2b results By Investing.com - Investing.com South Africa
PTAB Finds Hormone Treatment Patent Claims Invalid - Law360
Spruce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Supplementary Review: IBEX Limited (IBEX), November 19, 2024 - MSN
ARMISTICE CAPITAL, LLC Acquires New Stake in Spruce Biosciences Inc - GuruFocus.com
Spruce Biosciences Inc (SPRB) Quarterly 10-Q Report - Quartzy
Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Scholz Advisers Slash German Growth Forecast for Next Year - Yahoo Finance
Spruce Biosciences' SWOT analysis: tildacerfont's fate hangs on Q4 trial results - Investing.com Canada
EchoStar Q3 Earnings Lag Estimates on Lower Revenues, Stock Down 13% - Yahoo Finance
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spruce Biosciences Inc Stock (SPRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Charlton Ralph William III | CHIEF MEDICAL OFFICER |
Dec 10 '24 |
Option Exercise |
0.00 |
106,400 |
0 |
161,773 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 16 '24 |
Option Exercise |
0.00 |
75,750 |
0 |
363,841 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '24 |
Option Exercise |
0.00 |
154,000 |
0 |
356,776 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Option Exercise |
0.00 |
200,700 |
0 |
506,796 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '24 |
Option Exercise |
0.00 |
358,800 |
0 |
466,121 |
| Novo Holdings A/S | 10% Owner |
Mar 21 '24 |
Sale |
0.75 |
465,021 |
350,951 |
2,550,000 |
| Novo Holdings A/S | 10% Owner |
Mar 18 '24 |
Sale |
0.77 |
842,020 |
647,008 |
3,968,000 |
| Novo Holdings A/S | 10% Owner |
Mar 19 '24 |
Sale |
0.76 |
593,000 |
447,715 |
3,375,000 |
| Novo Holdings A/S | 10% Owner |
Mar 20 '24 |
Sale |
0.73 |
359,979 |
264,081 |
3,015,021 |
| Novo Holdings A/S | 10% Owner |
Mar 14 '24 |
Sale |
0.89 |
1,912,316 |
1,698,902 |
4,810,020 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):